ProCE Banner Activity

Integrating Practice-Changing Findings to Improve the Care of Patients With Myeloma

Multimedia
Tune in to this on-demand Webcast in which Carol Ann Huff, MD, provides expert perspective on the optimal treatment of patients with myeloma, including discussion of recently approved agents and adverse event management.

Released: January 25, 2018

Expiration: January 24, 2019

No longer available for credit.

Share

Faculty

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Celgene

Takeda Oncology

Learning Objectives

  • Apply new diagnosis and staging criteria to determine optimal timing of treatment initiation for patients with myeloma
  • Plan individualized treatment for patients with newly diagnosed myeloma based on patient characteristics and tumor biology/genetics using current guidelines and emerging therapeutic options
  • Integrate recently approved agents into existing treatment strategies for patients with relapsed/refractory myeloma
  • Manage disease- and treatment-related symptoms in patients with myeloma

Program Director Disclosure

Program Director

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Novartis, Roche, and Takeda Oncology and funds for research support from AstraZeneca.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.